Telomerase Activity Is Decreased in Peripheral Blood Mononuclear Cells of Hemodialysis Patients
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Background: Telomerase preserves telomere length and structure, preventing cellular senescence, which is associated with alteration of the chromosomal ends. We hypothesized that telomerase activity is altered in peripheral blood mononuclear cells (PBMCs) of hemodialysis (HD) patients. To investigate this hypothesis as well as the relationship between telomerase and inflammation, we measured the activity of this reverse transcriptase as well as the level of several inflammatory markers in PBMCs and serum of an end-stage renal failure (ESRF) population and a non-renal-failure group of subjects. Methods: In PBMCs isolated from 42 HD and 39 non-renal-failure subjects of the same age (51.0 ± 12.4 and 51.4 ± 12.1 years, respectively) telomerase activity was measured using PCR-ELISA; the method was based on the telomeric repeat amplification protocol. Results: Telomerase activity in PBMCs was detected in 18 (42.9%) HD and 28 (71.8%) non-renal-failure subjects (p = 0.013). Among positive subjects, percent telomerase activity in PBMCs was significantly higher in non-renal- failure (117 ± 112 %) than in HD (47.6 ± 57.1 %) subjects (p = 0.008). Detectable telomerase activity was lower in long-term than in short-term HD patients (13.3 ± 8.9 vs. 75.0 ± 64.8%, respectively, p = 0.015). Although higher in HD group, inflammatory indexes (C-reactive protein, interleukin-6, IL-6, soluble IL-6 and soluble gp130) were not correlated to telomerase activity in PBMCs. Conclusion: Telomerase activity in PBMCs is reduced in HD patients. It seems that, at least in this type of cell in this population, defense from senescence, as assessed by telomerase activity, is altered and associated with the chronicity of uremia/HD procedure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, DDR activation and senescence alone or in combination with insults such as infections, lipopolysaccharides, uraemic toxins and dialysis treatments, can contribute to CKD139,140.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [140]
Citations
Cites
1 retracted
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y., Mitsiades, C. S., Mitsiades, N., Chauhan, D., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2002) · PubMed · Cited by 198
RetractedSpecific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Accelerated telomere shortening in response to life stress
Epel, E. S., Blackburn, E. H., Lin, J., Dhabhar, F. S., Adler, N. E., Morrow, J. D., & Cawthon, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407162101 · Cited by 3,002
Telomeres and telomerase: Their mechanisms of action and the effects of altering their functions
Blackburn, E. H. (2005) · FEBS Letters · doi:10.1016/j.febslet.2004.11.036 · Cited by 838 · cited 1×
“Cellular senescence is an important aspect of cell behavior and seems to occur either after an extended period of cell divisions (‘replicative senescence’) or more rapidly in response to various physiologic stresses (‘stress-induced senescence’) [ , ,”
BackgroundSenescence Induced by Altered Telomere State, Not Telomere Loss
Karlseder, J., Smogorzewska, A., & de Lange, T. (2002) · Science · doi:10.1126/science.1069523 · Cited by 796
Telomerase maintains telomere structure in normal human cells
Kenichi, M., Yu, E. Y., Shilagardi, K., Ben‐Porath, I., Currier, J. L., Metz, G. B., Brooks, M. W., Kaneko, S., Seishi, M., DeCaprio, J. A., et al. (2006) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University) · Cited by 738
Beginning to Understand the End of the Chromosome
Cech, T. R. (2004) · Cell · doi:10.1016/s0092-8674(04)00038-8 · Cited by 421 · cited 1×
“Cellular senescence is an important aspect of cell behavior and seems to occur either after an extended period of cell divisions (‘replicative senescence’) or more rapidly in response to various physiologic stresses (‘stress-induced senescence’) [ ,”
BackgroundWhen cells get stressed: an integrative view of cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420663 · Cited by 404 · cited 1×
“Cellular senescence is an important aspect of cell behavior and seems to occur either after an extended period of cell divisions (‘replicative senescence’) or more rapidly in response to various physiologic stresses (‘stress-induced senescence’) [”
BackgroundPhenotypic and functional characteristics of circulating monocytes of elderly persons☆
Sadeghi, H. M., Schnelle, J. F., Thomas, J. K., Nishanian, P., & Fahey, J. L. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(99)00065-0 · Cited by 165
Evidence that exposure of the telomere 3′ overhang sequence induces senescence
Li, G.-Z., Eller, M. S., Firoozabadi, R., & Gilchrest, B. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0235444100 · Cited by 160 · cited 1×
“Taking into consideration the findings of both studies, it seems that not only premature senescence, reflected by telomere shortening, but also the potential of preserving telomere length and structure by telomerase activity is altered, at least in PBMCs, in this population. This last finding should be of importance,…”
Background
Cited by
Telomere dysfunction in ageing and age-related diseases
Rossiello, F., Jurk, D., Passos, J. F., & d’Adda di Fagagna, F. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00842-x · Cited by 754
Carrero, J. J., Stenvinkel, P., Fellström, B., Qureshi, A. R., Lamb, K., Heimbürger, O., Bárány, P., Radhakrishnan, K., Lindholm, B., Soveri, I., et al. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01890.x · Cited by 186
Healthy aging and disease: role for telomere biology?
Zhu, H., Belcher, M., & van der Harst, P. (2011) · Clinical Science · doi:10.1042/cs20100385 · Cited by 161
The Telomere/Telomerase System in Chronic Inflammatory Diseases. Cause or Effect?
Kordinas, V., Ioannidis, A., & Chatzipanagiotou, S. (2016) · Genes · doi:10.3390/genes7090060 · Cited by 140
“In addition, hTERT exhibited low levels of expression in intermediate stages of the disease but not in dialysis patients while our study also confirmed the inflammatory status of these patients [130,131].”
BackgroundResultSelf-citationTsitsimpikou, C., Tzatzarakis, M. N., Fragkiadaki, P., Kovatsi, L., Stivaktakis, P. D., Kalogeraki, A. M., Kouretas, D., & Tsatsakis, A. M. (2012) · Toxicology · doi:10.1016/j.tox.2012.11.002 · Cited by 107
“The method for the isolation of PBMCs is described elsewhere (Tsirpanlis et al., 2006).”
MethodStatins, inflammation and kidney disease
Krane, V., & Wanner, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.62 · Cited by 91
Cardiotoxicity in rabbits after a low-level exposure to diazinon, propoxur, and chlorpyrifos
Zafiropoulos, A., Tsarouhas, K., Tsitsimpikou, C., Fragkiadaki, P., Germanakis, I. E., Tsardi, M., Maravgakis, G., Goutzourelas, N., Vasilaki, F., Kouretas, D., et al. (2014) · Human & Experimental Toxicology · doi:10.1177/0960327114532384 · Cited by 83
“The method for the isolation of PBMCs is described elsewhere.(37) PBMC isolation with density gravity centrifugation from diazinontreated animals did not result in enough DNA to proceed with the PCR elongation/amplification step of the commercial telomerase activity kit due to technical errors.”
MethodUremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight
Chao, C., & Lin, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126270 · Cited by 82
“Telomerase activity has been shown to be reduced in the mononuclear cells of patients under hemodialysis and has become even lower with increasing dialysis vintage [38].”
BackgroundRentoukas, E., Tsarouhas, K., Kaplanis, I., Korou, E., Nikolaou, M., Marathonitis, G., Kokkinou, S., Haliassos, A., Mamalaki, A., Kouretas, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035739 · Cited by 65
“The method for detection of telomerase activity and isolation of PBMC is described elsewhere [14].”
MethodDrivers and mechanisms of cognitive decline in chronic kidney disease
Capasso, G., Franssen, C. F. M., Perna, A. F., Massy, Z. A., Menzies, R. I., Zoccali, C., Tessitore, A., Nedergaard, M., Okusa, M. D., Ortíz, A., et al. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-025-00963-0 · Cited by 66
“Telomere shortening, another ageing marker, is observed in people with CKD and telomerase activity is decreased in peripheral blood mononuclear cells of people treated with haemodialysis compared with those without kidney failure 89 .”
Tsirpanlis, G. I. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.035 · Cited by 59
Self-citationWu, C.-H., Hsieh, S.-C., Li, K.-J., Lu, M.-C., & Yu, C.-L. (2007) · Lupus · doi:10.1177/0961203307077155 · Cited by 47
n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease
Barden, A. E., O’Callaghan, N. J., Burke, V., Mas, E., Beilin, L. J., Fenech, M. F., Irish, A. B., Watts, G. F., Puddey, I. B., Huang, R., et al. (2016) · Nutrients · doi:10.3390/nu8030175 · Cited by 51
“Patients receiving haemodialysis have shorter telomeres and accelerated telomere shortening compared with the general population [4,5].”
BackgroundTelomere attrition, kidney function, and prevalent chronic kidney disease in the United States
Mazidi, M., Rezaie, P., Covic, A. C., Małyszko, J., Rysz, J., Kengne, A. P., & Banach, M. (2017) · Oncotarget · doi:10.18632/oncotarget.20706 · Cited by 44
“The limited existing evidence suggest that patients with end-stage renal disease (ESRD) may have shorter telomere and accelerated telomere shortening compared with the general population [14, 15].”
BackgroundAssociation between Kidney Function and Telomere Length: The Heart and Soul Study
Bansal, N., Whooley, M. A., Regan, M. C., McCulloch, C. E., Ix, J. H., Epel, E. S., Blackburn, E. H., Lin, J., & Hsu, C. (2012) · American Journal of Nephrology · doi:10.1159/000343495 · Cited by 45
“Clinical studies have reported that patients with end-stage renal disease (ESRD) may have shorter telomere length and accelerated telomere shortening compared with the general population.[4,5] Studies of severe heart failure patients have reported a strong correlation between reduced kidney function and shorter telome…”
BackgroundAssociation Between Telomere Length, Chronic Kidney Disease, and Renal Traits: A Systematic Review
Ameh, O. I., Okpechi, I. G., Dandara, C., & Kengne, A. P. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2016.0180 · Cited by 44
“Among hemodialysis patients, accelerated telomere attrition as well as reduced telomerase activity have also been demonstrated (Ramirez et al., 2005; Tsirpanlis et al., 2006).”
Fazzini, F., Lamina, C., Raschenberger, J., Schultheiss, U. T., Kotsis, F., Schönherr, S., Weissensteiner, H., Forer, L., Steinbrenner, I., Meiselbach, H., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.02.034 · Cited by 38
Aging and uremia: Is there cellular and molecular crossover?
White, W. E., Yaqoob, M. M., & Harwood, S. M. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i1.19 · Cited by 42
Borràs, M., Panizo, S., Sarró, F., Valdivielso, J. M., & Fernández, E. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.016 · Cited by 34
Vardavas, A. I., Özçağlı, E., Fragkiadaki, P., Stivaktakis, P. D., Tzatzarakis, M. N., Alegakis, A. K., Vasilaki, F., Kaloudis, K., Tsiaoussis, J., Kouretas, D., et al. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.03.002 · Cited by 33
“The method for the isolation of PBMCs is described elsewhere [26].”
MethodTelomere Attrition in Chronic Kidney Diseases
Levstek, T., & Podkrajšek, K. T. (2023) · Antioxidants · doi:10.3390/antiox12030579 · Cited by 30
“However, inflammatory markers were not correlated with telomerase activity [61].”
BackgroundTSIRPANLIS, G., CHATZIPANAGIOTOU, S., BOUFIDOU, F., KORDINAS, V., ZOGA, M., ALEVYZAKI, F., STAMATELOU, K., FRANGOU, E., SAVVA, L., & NICOLAOU, C. (2006) · Nephrology · doi:10.1111/j.1440-1797.2006.00697.x · Cited by 27
“In a previous study we did not find any correlation between C-reactive protein and IL-6 and telomerase activity in PBMC.(4) In the present study, TNFα was inversely associated with this enzyme activity.”
BackgroundMethodSelf-citationTelomeric G-Tail Length and Hospitalization for Cardiovascular Events in Hemodialysis Patients
Hirashio, S., Nakashima, A., Doi, S., Anno, K., Aoki, E., Shimamoto, A., Yorioka, N., Kohno, N., Masaki, T., & Tahara, H. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10010913 · Cited by 23
Raschenberger, J., Kollerits, B., Titze, S. I., Köttgen, A., Bärthlein, B., Ekici, A. B., Forer, L., Schönherr, S., Weißensteiner, H., Haun, M., et al. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.09.019 · Cited by 22
“In patients with dialysis-dependent renal failure reduced telomerase activity was described (Tsirpanlis et al. 2006), but nothing is known about telomerase activity in earlier CKD stages and during the course of CKD.”
BackgroundCellular Senescence and Inflammation: A Noteworthy Link
Tsirpanlis, G. I. (2009) · Blood Purification · doi:10.1159/000210032 · Cited by 22
“Telomere length as well as the activity of telomerase – that protects telomere structure – in circulating cells, are reduced and inversely correlated to renal function in the same patients [”
BackgroundSelf-citationStefanidis, I., Voliotis, G., Papanikolaou, V., Chronopoulou, I., Eleftheriadis, T., Kowald, A., Zintzaras, E., & Tsezou, A. (2015) · Artificial Organs · doi:10.1111/aor.12453 · Cited by 20
Vardavas, A. I., Fragkiadaki, P., Alegakis, A. K., Kouretas, D., Goutzourelas, N., Tsiaoussis, J., Tsitsimpikou, C., Stivaktakis, P. D., Carvalho, F. D., & Tsatsakis, A. M. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.12.026 · Cited by 20
Telomere Therapy for Chronic Kidney Disease
Akinnibosun, O. A., Maier, M. C., Eales, J., Tomaszewski, M., & Charchar, F. J. (2022) · Epigenomics · doi:10.2217/epi-2022-0073 · Cited by 19
Nikolouzakis, T. K., Vakonaki, E., Stivaktakis, P. D., Alegakis, A., Berdiaki, A., Razos, N., Souglakos, J., Tsatsakis, A., & Tsiaoussis, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683605 · Cited by 17
“(28), and TRAP-ELISA was conducted using TeloTAGGG Telomerase PCR ELISA (Roche Diagnostics Corp.”
MethodHill, C., Duffy, S., Kettyle, L. M., McGlynn, L. M., Sandholm, N., Salem, R. M., Thompson, A., Swan, E. J., Kilner, J., Rossing, P. R., et al. (2023) · Genes · doi:10.3390/genes14051029 · Cited by 16
“Reduced telomerase activity has also been reported in haemodialysis patients [38].”
Aging in Fabry Disease: Role of Telomere Length, Telomerase Activity, and Kidney Disease
Vujkovac, A. C., Novaković, S., Vujkovac, B., Števanec, M., Škerl, P., & Šabović, M. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000502909 · Cited by 15
Telomerase activity in patients with stage 2–5D chronic kidney disease
Kıdır, V., Aynalı, A., Altuntaş, A., İnal, S., Arıdoğan, B. C., & Sezer, M. T. (2017) · Nefrología (English Edition) · doi:10.1016/j.nefro.2017.03.025 · Cited by 16
Roles of telomeres and telomerase in age‑related renal diseases (Review)
Li, H., Wang, B., Li, D., Li, J., Luo, Y., & Dan, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11735 · Cited by 14
“despite telomerase activity gradually decreasing with cellular division, telomerase activation holds substantial promise for cKd treatment in the clinical setting (4), as numerous studies have proven the relationship between telomerase activity and cKd stages (50).”
BackgroundPinto, T. N. C., Fernandes, J. R., Arruda, L. B., Duarte, A. J. D. S., & Benard, G. (2021) · Clinics · doi:10.6061/clinics/2021/e2432 · Cited by 12
“The importance of telomerase upregulation is reinforced by recent studies showing that disruption of telomerase activity in unstimulated PBMCs from healthy donors results in cell proliferation, restricted lifespan, and altered telomere structure (‘telomere uncapping’) without changing the rate of overall telomere shor…”
BackgroundHenneghan, A. M., Fico, B. G., Wright, M. L., Kesler, S. R., & Harrison, M. (2021) · EXPLORE · doi:10.1016/j.explore.2021.10.011 · Cited by 10
Update of cellular senescence in kidney fibrosis: from mechanism to potential interventions
Yang, L., Ma, L., Fu, P., & Nie, J. (2025) · Frontiers of Medicine · doi:10.1007/s11684-024-1117-z · Cited by 13
Hill, C., Duffy, S., Coulter, T., Maxwell, A. P., & McKnight, A. J. (2023) · Genes · doi:10.3390/genes14030609 · Cited by 10
“showed decreased telomerase activity in leukocytes derived from 42 haemodialysis patients compared to 39 age-matched healthy controls, with telomerase activity significantly lower in long-term haemodialysis patients (median duration 100 months) compared to patients with a shorter duration of haemodialysis treatment (m…”
ResultFabry Disease: A New Model of Premature Ageing?
Kooman, J. P., Stenvinkel, P., & Shiels, P. G. (2019) · The Nephron journals/Nephron journals · doi:10.1159/000503290 · Cited by 8
Kordinas, V., Tsirpanlis, G. I., Nicolaou, C., Zoga, M., Ioannidis, A., Ioannidou, V., Bersimis, S., Petrihou, C., Savva, L., Legakis, N. J., et al. (2015) · Cellular & Molecular Biology Letters · doi:10.1515/cmble-2015-0016 · Cited by 9
Self-citationEndén, K., Tainio, J., Hou, M., Suominen, A. M., Pakarinen, M. P., Huang, T., Söder, O., Jalanko, H., Jahnukainen, K., & Jahnukainen, T. (2019) · Pediatric Transplantation · doi:10.1111/petr.13550 · Cited by 4
Telomere Biology in Senescence and Aging
Zhu, H., & van der Harst, P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397803-5.00007-1 · Cited by 5
Rudenko, T. E., Bobkova, I. N., Kamyshova, E. S., & Горелова, И. А. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh2017896102-109 · Cited by 3
Telomere Biology Alterations as a Mortality Risk Factor in CKD
Carrero, J. J., Shiels, P. G., & Stenvinkel, P. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.367 · Cited by 4
Kordinas, V., Nicolaou, C., Tsirpanlis, G. I., Ioannidis, A., Bersimis, S., Sabanis, N., Fragou, E., Tsiolaki, K., & Chatzipanagiotou, S. (2012) · International Journal of Nephrology · doi:10.1155/2012/154397 · Cited by 2
“In a previous study, we found that telomerase activity, an enzyme that provides an almost unlimited proliferation capacity when active, is decreased in peripheral blood mononuclear cells (PBMCs) from dialysis patients, when compared to healthy individuals [8].”
BackgroundSelf-citationDang, X., Xu, G., Li, H., Hao, Y., Zhang, X., Yu, X.-Y., Zhou, Z., Liu, X., Zhang, W., Lu, W., et al. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2568651 · Cited by 1
Introductory background to telomere shortening
Mantle, D. (2025) · Journal of Kidney Care · doi:10.12968/jokc.2025.0013
Metadata
- Authors
- Tsirpanlis, G., Chatzipanagiotou, S., Boufidou, F., Kordinas, V., Alevyzaki, F., Zoga, M., Kyritsis, I., Stamatelou, K., Triantafyllis, G., & Nicolaou, C.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2006
- Volume
- 26
- Issue
- 1
- Pages
- 91-96
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2079298382
- Cited by
- 47
- References
- 18
- Citations by year
- 2025: 4 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 5 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 1 · 2012: 5
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- American Journal of Nephrology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Roche Diagnostics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- telomerase activity, hemodialysis, peripheral blood mononuclear cells, end-stage renal disease, cellular senescence, telomere length, inflammation, C-reactive protein, interleukin-6, soluble gp130, uremia, dialysis duration
- MeSH terms
- Adult, Aged, Aged, 80 and over, C-Reactive Protein, Enzyme-Linked Immunosorbent Assay, Female, Renal Dialysis, Humans, Kidney Failure, Chronic, Leukocytes, Mononuclear, Male, Middle Aged, Interleukin-6, Polymerase Chain Reaction, Telomerase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.